Rationale and design of the enoximone clinical trials program.
about
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondAcute heart failure: inotropic agents and their clinical uses.Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.Chronic heart failure: current evidence, challenges to therapy, and future directions.Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsMedical management of advanced heart failure
P2860
Rationale and design of the enoximone clinical trials program.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Rationale and design of the enoximone clinical trials program.
@en
Rationale and design of the enoximone clinical trials program.
@nl
type
label
Rationale and design of the enoximone clinical trials program.
@en
Rationale and design of the enoximone clinical trials program.
@nl
prefLabel
Rationale and design of the enoximone clinical trials program.
@en
Rationale and design of the enoximone clinical trials program.
@nl
P2093
P1476
Rationale and design of the enoximone clinical trials program.
@en
P2093
Alastair D Robertson
Arthur M Feldman
Craig Hartman
David L Demets
Ellen B Roecker
Eric Eichhorn
Gwyn Evans
J William Freytag
Jean-Francois Liard
Jennifer Stewart
P304
P356
10.1016/J.CARDFAIL.2005.10.013
P577
2005-12-01T00:00:00Z